Dyslipidemia: Epidemiology Report and Forecast
Summary
Dyslipidemia is a medical condition characterized by abnormal lipid levels in the bloodstream, and includes the imbalance of cholesterol, low-density lipoprotein cholesterol (LDL-C), triglycerides (TG), and high-density lipoprotein cholesterol (HDL-C) (Pappan, Awosika and Rehman, 2024; Roland, 2026). Dyslipidemia increases the risk of cardiovascular disease (CVD), and has been associated with multiple diseases, including type 2 diabetes (T2D), neurodegenerative diseases, and cancer (Zhu et al., 2024). Dyslipidemia is classified into primary dyslipidemia and secondary dyslipidemia. Primary dyslipidemia refers to dyslipidemia caused by genetic mutations that affect lipid metabolism, such as familial hypercholesterolemia (FH), familial hypertriglyceridemia, familial combined hyperlipidemia, and familial dysbetalipoproteinemia. Secondary dyslipidemia is caused by lifestyle factors and disease conditions that alter lipid levels. Examples of causative factors include smoking, obesity, hypothyroidism, and chronic kidney disease (CKD) (Pappan, Awosika and Rehman, 2024; Roland, 2026).Risk factors of dyslipidemia include having a diet that is high in saturated fatty acids (SFA) or trans fatty acids (TFA) and low in soluble fiber, excessive alcohol use, tobacco use, low physical activity, hypothyroidism, and drug use (Liu and Peng, 2022; Mosteoru, Gaiţӑ and Gaiţӑ, 2023; Nordestgaard et al., 2013; Pappan, Awosika and Rehman, 2024; Park and Lee, 2025; Schoeneck and Iggman, 2021; Sousa et al., 2024; Tziomalos et al., 2011; Xu et al., 2025; Yanai and Yoshida, 2021). CVD, including coronary artery disease (CAD) and stroke, is a common comorbidity of dyslipidemia. Additionally, T2D, obesity, CKD, and liver disease act both as risk factors and comorbidities of dyslipidemia (Ahmmed et al., 2021; Allara et al., 2019; Charlat et al., 2025; Chelioti et al., 2021; Hedayatnia et al., 2020; Klop, Elte and Cabezas, 2013; Li et al., 2025; Zheng et al., 2024).
Scope
- The Dyslipidemia: Epidemiology Report and Forecast Model provide an overview of the risk factors, comorbidities, and global trends of dyslipidemia in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
- The report includes a 10-year epidemiology forecast for the total and diagnosed prevalent cases of dyslipidemia segmented by age (0-19 years, 20-64 years, 65 years and older) and sex, as well as the total prevalent cases of elevated LDL-C (≥130mg/dL), high TG (≥200mg/dL), very high TG (≥500mg/dL), and low HDL-C (< 40mg/dL [men, women 0-19 years], < 50mg/dL [women 20 years and older]), segmented by age. Additionally, the model also provides total and diagnosed prevalent cases of heterozygous FH segmented by age and sex, and total and diagnosed prevalence of mixed dyslipidemia, homozygous FH, FH, and elevated lipoprotein(a) (≥50mg/dL) for men and women of all ages.
Reasons to Buy
- The Dyslipidemia Epidemiology series will allow you to:
- Develop business strategies by understanding the trends shaping and driving the global dyslipidemia markets.
- Quantify patient populations in the global dyslipidemia markets to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for dyslipidemia therapeutics in each of the markets covered.
- Understand magnitude of the dyslipidemia population by age, and sex.
Table of Contents
1 Executive Summary
2 Epidemiology
3 Appendix
List of Tables
List of Figures
